The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor compound, alongside Surfactant , a triple GIP/GLP-1/GCG receptor agonist , https://socialmediastore.net/story22783664/tirzepatide-and-nad-a-triple-threat-strategy-to-metabolic-wellness